Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-77.6
Current
-68.8
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-77.6
=
Enterprise Value
665.3m INR
/
EBITDA
-8.6m INR
All Countries
Close
Market Cap EV/EBITDA
IN
Transgene Biotek Ltd
BSE:526139
525.8m INR -77.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 094.3
US
Abbvie Inc
NYSE:ABBV
316.5B USD 15.5
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD 21.7
US
Epizyme Inc
F:EPE
94.1B EUR -513.4
AU
CSL Ltd
ASX:CSL
135.7B AUD 19.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD 15.3
US
Seagen Inc
F:SGT
39.3B EUR -58.6
NL
argenx SE
XBRU:ARGX
36B EUR -109.3
EBITDA Growth EV/EBITDA to Growth
IN
Transgene Biotek Ltd
BSE:526139
Average EV/EBITDA: 16.4
Negative Multiple: -77.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 094.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.4 N/A N/A
AU
CSL Ltd
ASX:CSL
19.8
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More